The area under the curve (AUC) was 89.5% and 78.6% for TCGA and CGGA datasets, respectively (Fig. 2C,D) and these results indicated that CD96 can serve as a potential biomarker for the mesenchymal-molecular subtype of glioma. This evidence concerns the gene CD96 and central nervous system cancer.